Search Results
417 results
Your search is now limited to «Celgene» expert search.
ENDPOINTS 03/21/2019 13:48
Steve Tregay’s exit from Forma marked the end of a $757M collaboration with Celgene – Endpoints News.
More from ENDPOINTS:
FiercePharmaManufacturing 03/21/2019 10:47
Prior to this week’s escalation of the war between Starboard and BMS, analysts, by and large, were predicting investors would vote thumbs-up on the Celgene deal in April.
More from FiercePharmaManufacturing:
Zacks.com 03/21/2019 10:03
Starboard Value stated that Celgene has produced only three blockbuster products in 15 years, which raises concerns about Bristol-Myers’ assumption of significantly higher number of new blockbuster products in lesser time from Celgene’s current pipeline.
More from Zacks.com:
WN.com 03/21/2019 06:13
AIM: FIPP 21 March 2019 The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ('MAR'). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain. Frontier IP Group Plc ('Frontier IP' or the 'Group') Portfolio news - Exscientia and Celgene enter three-year AI drug discovery collaboration to accelerate drug discovery in oncology and autoimmunity Frontier IP, a specialist in commercialising university intellectual property, is pleased to note today's statement from portfolio company...
More from WN.com:
Seeking Alpha 03/20/2019 16:43
Based on the closing price of Bristol-Myers Squibb stock of $52.43 on January 2, 2019, the cash and stock consideration to be received by Celgene shareholders at closing are valued at $102.43 per Celgene share and one CVR worth one-time payment of $9.00 in cash.
More from Seeking Alpha:
STAT 03/19/2019 09:32
Bristol-Myers Squibb (BMY) and Starboard Value issued dueling presentations over the merits of the $74 billion bid the drug maker has made for Celgene (CELG.
More from STAT:
PR Newswire 03/19/2019 07:00
NEW YORK, March 19, 2019 /PRNewswire/ -- Starboard Value LP (together with its affiliates, "Starboard"), a stockholder of Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company")(NYSE: BMY), today announced that it has issued an investor presentation opposing the Company's proposed ...
More from PR Newswire:
Business Wire 03/19/2019 06:59
The registration statement was declared effective by the SEC on February 22, 2019, and Bristol-Myers Squibb and Celgene commenced mailing the definitive joint proxy statement/prospectus to stockholders of Bristol-Myers Squibb and Celgene on or about February 22, 2019.
More from Business Wire:
Reuters.com 03/14/2019 09:32
Drugmaker Bristol-Myers Squibb Co in January said it would buy Celgene for about $74 billion, to expand its pipeline of cancer drugs.
More from Reuters.com:
Channel NewsAsia (Singapore) 03/14/2019 09:15
US patent court rejects Alvogen's challenge for Celgene's Revlimid.
More from Channel NewsAsia (Singapore):
MedCity News 03/13/2019 13:08
Shortly after the Food and Drug Administration approved a combination using it with the first-ever immunotherapy drug to win the agency’s nod for breast cancer, a Celgene chemotherapy agent has failed in a registration-directed trial.
More from MedCity News:
Investor's Business Daily 03/12/2019 16:59
Celgene (CELG) and Novartis (NVS) could go head-to-head in a patent battle over Celgene's multiple sclerosis treatment ozanimod, an analyst said Tuesday.
More from Investor's Business Daily:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications